Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
SA Brown, N Pereira - Journal of personalized medicine, 2018 - mdpi.com
Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
[HTML][HTML] Acute coronary syndrome in the Asia-Pacific region
MY Chan, X Du, D Eccleston, C Ma… - international Journal of …, 2016 - Elsevier
More than 4.2 billion inhabitants populate the Asia-Pacific region. Acute coronary syndrome
(ACS) is now a major cause of death and disability in this region with in-hospital mortality …
(ACS) is now a major cause of death and disability in this region with in-hospital mortality …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs
J Kang, KW Park, T Palmerini, GW Stone… - Thrombosis and …, 2019 - thieme-connect.com
Background Prolonged dual anti-platelet therapy (DAPT) is intended to reduce ischaemic
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …
Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality
JM Siller-Matula, D Trenk, K Schrör, M Gawaz… - JACC: Cardiovascular …, 2013 - jacc.org
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …
secondary prevention of thrombotic events in vascular diseases. Within the past few years …
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated …
Background—The degree to which cytochrome P450 (CYP) 2C19 genotype influences the
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
JP Lewis, RB Horenstein, K Ryan… - Pharmacogenetics …, 2013 - journals.lww.com
Methods We genotyped a functional variant in CES1, G143E, in participants of the
Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n= 566) and in 350 patients …
Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n= 566) and in 350 patients …
Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity
R Shi, L Ge, X Zhou, WJ Ji, RY Lu, YY Zhang… - Thrombosis …, 2013 - Elsevier
OBJECTIVES: We aimed to investigate the relationship between platelet microRNA (miR-
223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart …
223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart …
ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis
J Su, J Xu, X Li, H Zhang, J Hu, R Fang, X Chen - 2012 - journals.plos.org
Background A number of investigators have evaluated the association between the ABCB1
polymorphism and clopidogrel responding, but the results have been inconclusive. To …
polymorphism and clopidogrel responding, but the results have been inconclusive. To …
Role of genetic testing in patients undergoing percutaneous coronary intervention
Introduction: Variability in individual response profiles to antiplatelet therapy, in particular
clopidogrel, is a well-established phenomenon. Genetic variations of the cytochrome P450 …
clopidogrel, is a well-established phenomenon. Genetic variations of the cytochrome P450 …